var data={"title":"Etomidate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Etomidate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6167?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=etomidate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Etomidate: Patient drug information&quot;</a> and <a href=\"topic.htm?path=etomidate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Etomidate: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169136\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Amidate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169163\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        General Anesthetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169139\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General anesthesia:</b> IV: Initial: 0.3 mg/kg (range: 0.2 to 0.6 mg/kg) over 30 to 60 seconds for induction of anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Supplementation to subpotent anesthetic agents:</b> IV: Administer smaller increments during short operative procedures to supplement subpotent anesthetic agents, such as nitrous oxide; individualize dosage (usually smaller than the original induction dose).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cushing syndrome (off-label use):</b> IV: Initial: 0.04 to 0.05 mg/kg/hour (usually equates to ~2.5 to 3 mg/hour). Titrate to serum cortisol of 18 to 29 mcg/dL (500 to 800 nmol/L) in a physiologically stressed patient <b>or</b> 5.5 to 11 mcg/dL (150 to 300 nmol/L) in a non-physiologically stressed patient. For complete blockade, titrate infusion rate to achieve a cortisol level &lt;5.5 mcg/dL (&lt;150 nmol/L). Hydrocortisone IV is required if complete blockade desired rather than partial blockade (&lsquo;block and replace&rsquo;) (Preda 2012). <b>Note:</b> Studies have not reported sedation at these etomidate doses; however, patients should be managed in an intensive care unit with sedation scoring every 2 hours initially for the first 24 hours, then every 12 hours. Cortisol levels should be measured every 4 to 6 hours (ES [Nieman 2015]; Preda 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Procedural sedation (off-label use):</b> IV: Initial: 0.1 to 0.2 mg/kg, followed by 0.05 mg/kg every 3 to 5 minutes as needed (Bahn, 2005; Miner, 2007; Vinson, 2002)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169150\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=etomidate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Etomidate: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>General anesthesia:</b> IV: Children &gt;10 years and Adolescents: Initial: 0.3 mg/kg (range: 0.2 to 0.6 mg/kg) over 30 to 60 seconds for induction of anesthesia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169140\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing; reduced doses may be required.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15881402\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution, risk of toxicity is greater in patients with renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15881403\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169120\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amidate: 2 mg/mL (10 mL, 20 mL) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/mL (10 mL, 20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/mL (10 mL, 20 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169106\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2364901\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer IV push over 30 to 60 seconds. Solution is highly irritating; avoid administration into small vessels; in some cases, preadministration of lidocaine may be considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169121\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>General anesthesia:</b> Induction of general anesthesia; as a supplement to subpotent anesthetic agents during maintenance of anesthesia for short operative procedures (eg, dilation and curettage, cervical conization).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725533\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cushing syndrome; Procedural sedation; Sedation for diagnosis of seizure foci</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169171\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Etomidate may be confused with etidronate</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169113\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Myoclonus (33%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Adrenal suppression</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea, vomiting (on emergence from anesthesia)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (30% to 80%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Musculoskeletal disease (transient skeletal movements)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Nystagmus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: Gastrointestinal: Hiccups</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Apnea, bradycardia, cardiac arrhythmia, decreased cortisol (decreased cortisol synthesis), hypertension, hyperventilation, hypotension, hypoventilation, laryngospasm, muscle spasm (masseter; Bozeman 2002), tachycardia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169124\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to etomidate or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169110\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal steroid production: Etomidate inhibits 11-B-hydroxylase, an enzyme important in adrenal steroid production. A single induction dose blocks the normal stress-induced increase in adrenal cortisol production for 6 to 8 hours, up to 24 hours in elderly and debilitated patients. Continuous infusion of etomidate for sedation in the ICU may increase mortality because patients may not be able to respond to stress. Administration by continuous infusion is not recommended by the manufacturer. No increase in mortality has been identified with a single dose for induction of anesthesia (McPhee 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: In a scientific statement from the American Heart Association, etomidate has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Risk of toxicity is greater in patients with renal impairment; use with caution and monitor renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: May induce cardiac depression in elderly patients, especially those with hypertension; may require lower doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric neurotoxicity: In pediatric and neonatal patients &lt;3 years and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on child or fetal brain development and may contribute to various cognitive and behavioral problems. Epidemiological studies in humans have reported various cognitive and behavioral problems, including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. No specific anesthetic/sedative has been found to be safer. For elective procedures, risks versus benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: When considering use, weigh etomidate hemodynamic properties against the high frequency of transient skeletal muscle movements.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced personnel: According to the manufacturer, etomidate should only be administered by experienced personnel trained in the administration of general anesthetics and in the management of complications encountered during the conduct of general anesthesia. Consult local regulations and individual institutional policies and procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299304\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169115\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8428&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Benznidazole: May enhance the adverse/toxic effect of Products Containing Propylene Glycol.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13763473\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Based on animal data, repeated or prolonged use of general anesthetic and sedation medications that block N-methyl-D- aspartate receptors and/or potentiate GABA activity may affect brain development. Human fetuses may be most vulnerable during the third trimester. Until additional information is available, the benefits and risks of maternal treatment with etomidate during pregnancy should be evaluated, especially for procedures lasting more than 3 hours. The ACOG recommends that pregnant women should not be denied medically indicated surgery or procedures, regardless of trimester. If the procedure is elective, it should be delayed until after delivery (ACOG 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20617116\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if etomidate is present in breast milk. The manufacturer recommends that caution be exercised when administering etomidate to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169118\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Cardiac monitoring; blood pressure; renal function (in renal impairment)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169109\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ultra-short-acting nonbarbiturate general anesthetic (benzylimidazole) used for rapid induction of anesthesia with minimal cardiovascular effects; produces EEG burst suppression at high doses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169123\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: 30 to 60 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: 1 minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Dose dependent: 2 to 3 minutes (0.15 mg/kg dose); 3 to 5 minutes (0.3 mg/kg dose); rapid recovery is due to rapid redistribution</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 2 to 4.5 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 76%; decreased protein binding resulting in an increased percentage of &ldquo;free&rdquo; etomidate in patients with renal failure or hepatic cirrhosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic and plasma esterases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal: 2.6 to 3.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: 7 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine ~75% (80% as metabolite; 2% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323138\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Amidate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (20 mL): $7.67</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Etomidate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (10 mL): $7.78</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169126\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Endata (CO);</li>\n      <li>Etomid (BD);</li>\n      <li>Etomidat-Lipuro (CH, LU);</li>\n      <li>Etomidato-Lipuro (AR);</li>\n      <li>Hypnomidate (AT, BE, BG, BR, CH, CZ, DE, ES, FR, GB, GR, HR, LU, MT, MX, NL, PL, PT, PY, RU, SI, TR, TW, ZA, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 474: nonobstetric surgery during pregnancy. <i>Obstet Gynecol</i>. 2011;117(2, pt 1):420-421. doi:10.1097/AOG.0b013e31820eede9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etomidate-drug-information/abstract-text/21252774/pubmed\" target=\"_blank\" id=\"21252774\">21252774</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amidate injection (etomidate) [prescribing information]. Lake Forest, IL: Hospira, Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bahn EL and Holt KR, &quot;Procedural Sedation and Analgesia: A Review and New Concepts,&quot; <i>Emerg Med Clin North Am</i>, 2005, 23(2):503-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etomidate-drug-information/abstract-text/15829394/pubmed\" target=\"_blank\" id=\"15829394\">15829394</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bozeman WP, Young S. Etomidate as a sole agent for endotracheal intubation in the prehospital air medical setting. <i>Air Med J</i>. 2002;21(4):32-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etomidate-drug-information/abstract-text/12087322/pubmed\" target=\"_blank\" id=\"12087322\">12087322</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ding Z and White PF, &ldquo;Anesthesia for Electroconvulsive Therapy,&rdquo; <i>Anesth Analg</i>, 2002, 94(5):1351-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etomidate-drug-information/abstract-text/11973219/pubmed\" target=\"_blank\" id=\"11973219\">11973219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Food and Drug Administration. FDA Drug Safety Communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women. US Food and Drug Administration Web site. <a href=\"https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm\" target=\"_blank\">https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm</a>. Updated December 14, 2016. Accessed May 26, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Godwin SA, Burton JH, Gerardo CJ, Hatten BW, Mace SE, Silvers SM, Fesmire FM; American College of Emergency Physicians. Clinical policy: procedural sedation and analgesia in the emergency department. <i>Ann Emerg Med</i>. 2014;63(2):247-58.e18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etomidate-drug-information/abstract-text/24438649/pubmed\" target=\"_blank\" id=\"24438649\">24438649</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hildreth AN, Mejia VA, Maxwell RA, et al, &ldquo;Adrenal Suppression Following a Single Dose of Etomidate for Rapid Sequence Induction: A Prospective Randomized Study,&rdquo; <i>J Trauma</i>, 2008, 65(3):573-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etomidate-drug-information/abstract-text/18784570/pubmed\" target=\"_blank\" id=\"18784570\">18784570</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McPhee LC, Badawi O, Fraser GL, et al. Single-dose etomidate is not associated with increased mortality in ICU patients with sepsis: analysis of a large electronic ICU database. <i>Crit Care Med</i>. 2013;41(3):774-783.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etomidate-drug-information/abstract-text/23318491/pubmed\" target=\"_blank\" id=\"23318491\">23318491</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16997421\"></a>Miner JR, Danahy M, Moch A, et al, &quot;Randomized Clinical Trial of Etomidate Versus Propofol for Procedural Sedation in the Emergency Department,&quot; <i>Ann Emerg Med</i>, 2007, 49(1):15-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etomidate-drug-information/abstract-text/16997421/pubmed\" target=\"_blank\" id=\"16997421\">16997421</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nieman LK, Biller BM, Findling JW, et al; Endocrine Society. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(8):2807-2831. doi: 10.1210/jc.2015-1818.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etomidate-drug-information/abstract-text/26222757/pubmed\" target=\"_blank\" id=\"26222757\">26222757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etomidate-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Preda VA, Sen J, Karavitaki N, Grossman AB. Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review. <i>Eur J Endocrinol</i>. 2012;167(2):137-143. doi: 10.1530/EJE-12-0274.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etomidate-drug-information/abstract-text/22577107/pubmed\" target=\"_blank\" id=\"22577107\">22577107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12023700\"></a>Vinson DR and Bradbury DR, &quot;Etomidate for Procedural Sedation in Emergency Medicine,&quot; <i>Ann Emerg Med</i>, 2002, 39(6):592-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etomidate-drug-information/abstract-text/12023700/pubmed\" target=\"_blank\" id=\"12023700\">12023700</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8428 Version 153.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F169136\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F169163\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F169139\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F169150\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F169140\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15881402\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15881403\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F169120\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F169106\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2364901\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F169121\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725533\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F169171\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F169113\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F169124\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F169110\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299304\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F169115\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13763473\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20617116\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F169118\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F169109\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F169123\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323138\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F169126\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8428|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=etomidate-patient-drug-information\" class=\"drug drug_patient\">Etomidate: Patient drug information</a></li><li><a href=\"topic.htm?path=etomidate-pediatric-drug-information\" class=\"drug drug_pediatric\">Etomidate: Pediatric drug information</a></li></ul></div></div>","javascript":null}